Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous
small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer
respirable particles.